02142 Overview

Stock Performance: HBM HOLDINGS-B (02142.HK) experienced a decline of 3.849%, with a short selling amount of $12.54 million and a ratio of 21.210%.

Strategic Collaboration: HBM HOLDINGS-B has entered a multi-year global collaboration with Bristol Myers Squibb to develop next-generation multi-specific antibodies.

Financial Terms: The agreement could yield HBM HOLDINGS-B up to $90 million in initial payments, with potential development and commercial milestones totaling up to $1.035 billion.

Royalty Structure: HBM HOLDINGS-B may also receive tiered royalties if Bristol Myers Squibb decides to advance all potential programs under the collaboration.